Navigation Links
Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher
Date:2/25/2013

SAN JOSE, Calif., Feb. 25, 2013 /PRNewswire/ -- Ariosa Diagnostics, maker of the non-invasive Harmony™ Prenatal Test for detection of common genetic conditions, has announced the election of Michael A. Aicher to its Board of Directors.

(Logo: http://photos.prnewswire.com/prnh/20130225/SF62999LOGO)

Mr. Aicher has had a very successful career in the molecular diagnostics industry having spent the last 20 years in leadership positions at National Genetics Institute (NGI), a wholly-owned subsidiary of Laboratory Corporation of America® Holdings (LabCorp®), and LabCorp.

As the co-founder and CEO of NGI, Mr. Aicher steered the implementation of an initial treatment model for HCV and secured the first FDA-approved HIV/HCV PCR tests for plasma donor screening, with 15 million donations per year tested. Under various leadership positions at LabCorp, he helped drive revenue and margins within the esoteric testing business. Recognition for Mr. Aicher includes distinction as an Ernst & Young "Entrepreneur of the Year" for Emerging Technologies. Mr. Aicher recently took on the CEO position at Omicia, a DNA sequencing informatics company.

"Ariosa Diagnostics is honored to welcome Michael Aicher to the board. His multiple fields of expertise in strategy and operations within molecular testing will greatly complement the existing board. We are pleased that he will share his leadership and guidance with the team at Ariosa," said Ken Song , MD, CEO of Ariosa.

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

CONTACT:
Jen Bruursema
Ariosa Diagnostics
408-229-7539
jbruursema@ariosadx.com


'/>"/>
SOURCE Ariosa Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ariosa Diagnostics Announces Nationwide Launch of the Harmony™ Prenatal Test Through LabCorp
2. Ariosa Diagnostics Announces Publication of Study on Influential Factors Affecting Fetal DNA Concentration in Blood of Pregnant Women
3. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
4. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
5. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
6. S.E.D. Labs to be Acquired by Quest Diagnostics
7. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
8. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
9. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
10. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
11. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Cancer experts from Austria, Hungary, Switzerland, ... a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just ... now. , Biomarkers are components in the blood, tissue or body fluids ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):